Evidence map›Paper›PMID 33967751›Full record

ArticleFrontiers in pharmacology2021

Unraveling Gene Fusions for Drug Repositioning in High-Risk Neuroblastoma.

Zhichao Liu, Xi Chen, Ruth Roberts, Ruili Huang, Mike Mikailov, Weida Tong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Frontiers in pharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Zhichao LiuDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
Xi ChenDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
Ruth RobertsApconiX, BioHub at Alderley Park, Alderley Edge, United Kingdom.
Ruili HuangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, United States.
Mike MikailovOffice of Science and Engineering Labs, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, United States.
Weida TongDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, United States.
United States Food and Drug Administration · USCenter for Devices and Radiological Health · USNational Center for Advancing Translational Sciences · USNational Center for Toxicological Research · USUniversity of Birmingham · GB

Funding

Toxicology in the 21st Century Program (Tox21) - Computational ToxicologyZIATR000040 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI HUANG, RUILI · 2016 to 2025
$3.5M
6 · The paper itself

Abstract

High-risk neuroblastoma (NB) remains a significant therapeutic challenge facing current pediatric oncology patients. Structural variants such as gene fusions have shown an initial promise in enhancing mechanistic understanding of NB and improving survival rates. In this study, we performed a comprehensive

Indexed as

drug repositioninggene fusionsneuroblastomanext-generation sequencingprecision medicine 3structural variants

Identifiers

PMID33967751
PMCPMC8105087
OpenAlexW3157496612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.